Silent Presentation, Significant Threat: Cold Agglutinin Syndrome After Haploidentical Hematopoietic Stem Cell Transplantation

Documenti analoghi

• Haploidentical Hematopoietic Stem Cell Transplantation With Anti‐Thymocyte Globulin in the Treatment of Older Adults With Hematological Malignancy
  di: Xin Kong, et al.
  Pubblicazione: (2026)
• Adenovirus‐Associated Opsoclonus After Allogeneic Hematopoietic Stem Cell Transplantation
  di: Toru Miyajima, et al.
  Pubblicazione: (2026)
• Real‐World Use of Rituximab in the Treatment of Cold Agglutinin Disease in the United States: A Retrospective Study
  di: Caroline Piatek, et al.
  Pubblicazione: (2025)
• Prompt Autologous Hematopoietic Stem Cell Transplant in Patients With Large B‐Cell Lymphoma Is Associated With Lower Rates of Progression of Disease Prior to Transplant
  di: Erin A. Dean, et al.
  Pubblicazione: (2025)
• Effect of Early Administration of Anti‐MRSA Drugs for Febrile Neutropenia in Allogeneic Hematopoietic Cell Transplantation
  di: Anna Akaogi, et al.
  Pubblicazione: (2026)